Liste modèle des médicaments essentiels

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IV: 250 µg in single-dose vial ◦ Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies Rh incompatibility reaction

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 150 IU per mL in vial ◦ Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-rabies virus monoclonal antibodies

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins ◦ Parenteral > General injections > IM: 500 IU in vial	Tetanus

Antirabies hyperimmune serum

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule	Rabies

Antivenom immunoglobulin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Antivenom sera

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IV:	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Diphtheria antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial	Need for immunization against diphtheria alone

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Snake antivenom

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ .	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Tetanus antitoxin

Section	Indications
Immunologicals > Sera, immunoglobulins and monoclonal antibodies ◦ Parenteral > General injections > IM: 50000 IU in vial	Tetanus